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Context: Tissue cortisol exposure is under the control of the isozymes of 11-hydroxysteroid de-
hydrogenase (11-HSD). 11-HSD1 in vivo, acts as an oxoreductase converting inactive cortisone to
active cortisol. We hypothesized that 11-HSD1 activity is dysregulated in obesity and alters fol-
lowing bariatric surgery induced weight loss in different tissues.
Methods:We recruited 21 patients prior to undergoing bariatric surgery and performed cortisol
generation profiles (following oral cortisone administration), urinary corticosteroid metabolite
analysis, adipose tissue microdialysis, and tissue gene expression before and after weight loss,
following bariatric surgery. Archived tissue samples from 20 previous bariatric surgery patients
were also used for tissue gene expression studies.
Results:Geneexpression showedapositive correlationwith 11-HSD1andBMI inomental adipose
tissue (OM) (r0.52,P .0001)butnot sc adipose tissue (r0.28,P .17). 11-HSD1expression
in liver negatively correlatedwith bodymass index (BMI) (r0.37, P .04). 11-HSD1 expression
in sc adipose tissue was significantly reduced after weight loss (0.41 0.28 vs 0.17 0.1 arbitrary
units, P  .02). Following weight loss, serum cortisol generation increased during a cortisol gen-
erationprofile (areaunder the curve26 76816 880 vs 47 57916 086nmol/L/minute,P .0001.)
Urinary corticosteroid metabolites demonstrated a significant reduction in total cortisol metab-
olites after bariatric surgery (15 224  6595 vs 8814  4824 g/24 h, P  .01). Microdialysis of sc
adipose tissue showed a threefold reduction in cortisol/cortisone ratio after weight loss.
Conclusions: This study highlights the differences in tissue specific regulation of cortisol metabolism in
obesity and after weight loss. Following bariatric surgery hepatic 11-HSD1 activity increases, sc adipose
tissue 11-HSD1activity is reduced and total urinary cortisolmetabolites are reduced indicating apossible
reduction inhypothalamicpituitary adrenal axis drive. 11-HSD1expression correlates positivelywithBMI
inomentaladiposetissueandnegativelywithinhepatictissue.11-HSD1expressionisreducedinscadipose
tissue after weight loss. (J Clin Endocrinol Metab 100: 1434–1444, 2015)
Obesity has reached epidemic proportions worldwide,where severe obesity (bodymass index [BMI] 40)
is commonplace (1–4). Obesity increases the risk of de-
veloping diabetes, cancer, and cardiovascular disease and
is associated with an increased mortality (5–9). Patients
with glucocorticoid (GC) excess (Cushing’s syndrome)
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pressure; bp, base pairs; DHEA, dehydroepiandrosterone; F/E, cortisol to cortisone ratio; GC, glu-
cocorticoid; GC/MS, gas chromatograph mass spectrometry; GR, glucocorticoid receptor; HDL,
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RYGB, Roux EnYGastric Bypass; TAG, trigaclycerol; THE, tetrahydrocortisone; THF, tetrahydrocor-
tisol; UFE, urinary free cortisone; UFF, urinary free cortisol; VLCD, very low calorie diet.
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bear a strikingly similar phenotype to patients with obe-
sity. In obesity however, circulating serumGC concentra-
tions are in the normal range or lower than controls (10).
Circulating serumGC concentrations are regulated by the
hypothalamic pituitary adrenal (HPA) axis. Tissue corti-
sol metabolism is under the control of the isozymes of the
11-hydroxysteroid dehydrogenase (11-HSD) system.
In vivo, 11-HSD1 acts primarily as an oxoreductase con-
verting inactive cortisone to active cortisol. Dysregulated
11-HSD1 activity has been implicated in obesity, meta-
bolic, and inflammatory diseases (11, 12).
Most studies examining 11-HSD1 activity and ex-
pression in adipose tissue have been carried out using sc
adipose tissue. In general, they show 11-HSD1 activity
and expression is increased in obesity (13–17). However,
some studies have not found an increase in sc tissue 11-
HSD1 expression (18). Conflicting data on changes in
11-HSD1 expression following dietary weight loss have
beenpublished (19, 20), but gastric bypass inducedweight
loss, resulted in reduced expression in 1 study (21). Data
analyzing the omental adipose depot are understandably
more sparse, but increased expression of 11-HSD1
mRNAlevels inomental adipose tissuehavebeen reported
in obesity (18, 23–25, 30). In hepatic tissue the results are
also conflicting; 11-HSD1 expression has been shown to
be elevated inobesity (24), correlatingpositivelywithmet-
abolic disease (26), but other studies have reported a re-
duction in obese patients (13) and increase following
short-term dietary weight loss (19). Analyses of urinary
corticosteroid metabolites are similarly mixed. Urinary
cortisol metabolites correlate positively with increasing
waist circumference (27). Urinary cortisol metabolite
analysis shows reduced 11-HSD1 activity in central obe-
sity (28). Following weight loss, urinary glucocorticoids
andmetabolites havebeen reported tobe reduced (27, 29).
As increased activity of 11-HSD1may augment tissue
cortisol exposure and contribute to a metabolically un-
healthy phenotype (30), the prospect of specific 11-
HSD1 inhibitors raises the possibility of these drugs as
potential treatments for obesity and the metabolic syn-
drome (11, 31, 32). Early trials examining 11-HSD1 in-
hibitors in diabetes andmetabolic syndrome (33, 34) have
been reported, but long-term data are lacking. Of note, all
published clinical trials looking at specific 11-HSD1 in-
hibitors have shown modest but significant weight loss
(33–35).
The interpretation of studies to date is limited by the
lack of data from multiple tissue depots in an individual
patient. Not all studies utilize a cortisol generation profile
to measure hepatic 11-HSD1 activity, instead of relying
on urinary corticosteroid metabolite ratios, which may
reflectmore global 11-HSD1activity. Further studies are
required to establish the global and tissue-specific role of
11-HSD1 in obesity and following weight loss.
We aimed to establish the activity and expression of
11-HSD1 inmultiple tissue depots by severalmethods of
assessment (urinary corticosteroid metabolite analysis,
cortisol generation profile, in vivo adipose tissue micro-
dialysis, and PCR) in obese individuals and the effect of
weight loss.
Materials and Methods
Patients, ethics, and anthropometric
measurements
The study received ethical approval from the Ethics Commit-
tee of St Vincent’s University Hospital group. Participants were
recruited between autumn 2010 and spring 2013. We recruited
participants who were awaiting bariatric surgery in St Colum-
cille’sHospital, Loughlinstown,Dublin. Patients awaitingRoux
En Y Gastric Bypass (RYGB) had attended a multidisciplinary
team for at least 12 months with input from monthly physio-
therapy, psychology, and nutritional support and were deemed
appropriate candidates for RYGB surgery, having failed conser-
vative measures for weight loss. Participants whowere recruited
gave informed consent and attended detailed assessment (as out-
lined below) prior to surgery with repeat testing after surgery
(Figure 1). Patients were operated on between April 2011 and
April 2013. In addition, archived tissue samples from patients
whounderwentRYGBsurgerybetween2005and2010andgave
Figure 1. Baricort study protocol involving baseline, surgical, and postoperative testing
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informed consent for further testing were used for baseline gene
expression analysis.
Exclusion criteria included current or prior steroid usewithin
the previous 6 months or significant weight fluctuations 6
months prior to surgery or recent illness at time of assessment,
pregnancy, age 70 years or 18 years, and persons unable to
give informed consent.
Assays
Presurgical blood tests including cholesterol profile, electro-
lytes, liver profile, blood counts, thyroid function tests, and glu-
cose indices were all carried out with in-hospital assays. Serum
glucose was collected in sodium fluoride tubes and measured
using the hexokinase methodology in an automated analyzer
(Olympus AU640). Serum total cholesterol, low-density lipo-
protein (LDL), and high-density lipoprotein (HDL) cholesterol,
and trigaclycerol (TAG) concentrations were collected in serum
tubes and measured using enzymatic reagents (Olympus
AU640). Seruminsulinwasmeasuredusinganautomatedmono-
clonal antibody-based two-site immunoenzymometric assay
(AIA-1800 system, Tosoh Europe NV), and glycosylated hemo-
globin (HbA1c) wasmeasured with an automatedHPLC instru-
ment-reagent system (model HLC-723 G7; Tosoh Europe NV).
Cortisol generation profile
Participants were studied after overnight fasting. They at-
tended for testing at 9:00 AM after an overnight fast and having
ingested 2mg of dexamethasone the previous night at 11:00 PM
to suppress endogenous adrenal cortisol production. The dose of
2mgof dexamethasonewas chosenbasedon thehighBMIof our
patient cohort (mean BMI  52.13  7.5 kg/m2) given that
previous papers documented difficulty in suppressing adrenal
cortisol production in obese cohorts (36). An iv cannula was
inserted in the antecubital fossa and a sc adipose tissue micro
dialysis catheter (CMA60, CMA Microdialysis) was inserted,
under local anesthetic, 10 cm lateral to the umbilicus. The use of
CMA microdialysis catheters has been described previously by
our group (37). After a flush sequence (15 L over 5 min) mi-
crodialysis was performed at a rate of 0.3 L per minute and
continued for 240 minutes. After baseline fasting bloods were
taken, participants were given 25 mg of oral cortisone acetate.
Following this, serum and microdialysis samples were taken ev-
ery 30minutes for 240minutes. Serum sampleswere centrifuged
andmicrodialysis vialswere stored at80°Cuntil analysis using
liquid chromatography tandem mass spectrometry.
Urinary glucocorticoid metabolite profile
Participants completed a 24-hour urine collection for corti-
sol, cortisone, andglucocorticoidmetabolite analysis (38) before
surgery and again after surgery, followingweight loss. The urine
collections were carried out on a separate occasion from the
cortisol generation profile, when no dexamethasone was taken.
The volume of the urine was recorded, and 15 mL aliquots were
stored at 20°C until analysis using gas chromatograph mass
spectrometry (GC/MS) as previously described (38). Total cor-
tisolmetabolites include tetrahydrocortisol (THF), 5-THF, tet-
rahydrocortisone (THE), cortols and cortolones and free cortisol
metabolites. Urinary (THF  5-THF)/THE is regarded as an
index of global 11-HSD activity, if the ratio of urinary free
cortisol (UFF) to urinary free cortisone (UFE) is unaltered [re-
flecting specifically the activity of renal 11-HSD2], any changes
in this ratio result from alterations in 11-HSD1 activity. Thus,
a reduction in theurinary (THF5-THF)/THEratio correlates
well with impaired generation of serum cortisol from orally ad-
ministered cortisone acetate indicative of reduced 11-HSD1
activity (28).
Steroid extraction and analysis from urine, serum,
and microdialysis fluid
Corticosteroid extraction and analysis from urine was per-
formed using GC/MS as described in detail previously by our
group (38–40). For corticosteroid extraction and analysis from
serum samples, liquid chromatography tandem mass spectrom-
etry was used as previously described by our group (41). Due to
low volumes of dialysate, microvial samples were pooled into 2
groups (pre- and postoperatively) according to the various time
points. The semipermeable membrane in the microdialysis cath-
eter (20 kilodalton limit) only allows collection of free unbound
cortisol from the sc adipose tissue. Serum measurements repre-
sent unbound cortisol. Urine measurements represent total cor-
ticosteroid metabolites (steroids are deconjugated from sulfated
andglucuronidated toproducea total steroidprofile byGC/MS).
Intra operative tissue sampling
Tissue samples were collected during surgery. Omental, sc
adipose tissue, and hepatic tissue biopsies were placed immedi-
ately into RNA later (Life Technologies) and stored at 4°C over-
night. The following day, the samples were frozen and stored at
80°C until analysis. Repeat sc adipose tissue biopsies were
obtained more than 6 months following surgery (mean time of
biopsy was 14 mo). Under an aseptic technique and using 2%
lignocaine as analgesia, a 1-cm incision was made 10 cm lateral
to the umbilicus and a small sample of adipose tissue was re-
moved. These sc adipose samples were immediately placed into
RNA later and stored as above.
RNA extraction
Total RNA was extracted from tissue using the Tri-Reagent
(Trizol Life Technologies) single step system.Concentrationwas
determined spectrophotometrically at OD260.
Reverse transcription
In a 20-L volume, 500 ng of total RNAwas incubated with
0.8 L random hexamers, 2 L deoxyribonucleotide triphos-
phates (10), 1 L RNase inhibitor, 1 L Multiscribe reverse
transcriptase, 5.5 mM MgCl, and 1 L reaction buffer. The
reverse transcription reaction was carried out at 25°C for 10
minutes and 37°C for 120 minutes before the reaction was ter-
minated by heating to 85°C for 5 minutes. Reagents were pur-
chased from Applied Biosystems.
Pre-PCR amplification
For pre-PCR amplification of cDNA, Taqman Pre-Ampmas-
ter mix and pooled Taqman assays were used. Pre-PCR ampli-
fication reaction was done at 5 L containing 2.5 L Taqman
Pre-Amp Master Mix (2), 1.25 L of pooled Taqman assay
mix, and 1.25 L cDNA. Preamplification PCRwas carried out
at 1 cycle of 95°C for 10 minutes followed by 14 cycles of 95°C
for 15 seconds and then 60°C for 4 minutes. After preamplifi-
cation, the product was diluted 1:5 and stored at 20°C.
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Real time PCR
Real time PCR (RT-PCR) was carried out using the Fluidigm
platform as described previously (42). The sequence for 11ß-
HSD1 was 5	-AGGAAAGCTCATGGGAGGACTAG-3	 (anti-
sense, 23 bp), 5	-ATGGTGAATATCATCATGAAAAAGAT
TC-3	 (sense, 28 base pairs [bp]), and 11ß-HSD1TaqManprobe
5	-CATGCTCATTCTCAACCACATCACCAACA-3	 (29 bp).
Reactions were performed in singleplex in 10-L volumes on
96-well plates in reaction buffer containing 2  TaqMan Uni-
versal PCR Master Mix (Applied Biosystems). Primers and
probes were supplied by Applied Biosystems as premade “assay
on demand.” All reactions were normalized against the house-
keeping gene 18S rRNA, provided as a preoptimized control
probe. All target geneswere labeledwith FAM, and the reference
genewithVIC.The reaction conditionswere as follows: 95°C for
10 minutes, then 40 cycles of 95°C for 15 seconds, and 60°C for
1 minute. Data were obtained as Ct values (Ct  cycle number
atwhich logarithmic PCRplots cross a calculated threshold line)
and used to determine 
Ct values [
Ct  (Ct of the target
gene)  (Ct of the reference gene)]. Data were expressed as ar-
bitrary units [arbitrary units (AU)  1000 x(2
ct)].
Postoperative cortisol generation profile
Participants in this study had normal surgical follow-up with
regular clinic attendances at 6 weeks and 12 weeks postopera-
tively and then at 3-month intervals. Participants returned for
repeat testing no earlier than 6 months postoperatively. The
mean length of time for postoperative reassessment following
bariatric surgery was 9.3  2.2 months.
Postoperative sc adipose tissue biopsy
On a separate visit to the cortisol generation profile, with no
dexamethasone suppression, the participant attended a sc adi-
pose tissue biopsy. Under local anesthetic (5 mL 2% lignocaine)
adipose tissuewas biopsied from under the skin of the abdomen,
10 cm lateral and 5 cm inferior to the umbilicus. Adipose tissue
was stored initially in RNA later and then at 80°C until
analysis.
Statistical analysis
Results are expressed asmeans SD for parametric data and
medians and interquartile ranges for non-Gaussian data. Statis-
tical analyses comparing groups were done using Student’s t-test
andMannWhitney U-test for non-Gaussian datasets. Spearman
and Pearson correlation tests were used to analyze associations
between datasets. Figures and statistics were performed using
Graph Pad Prism version 6.
Patients
All participants were Caucasian. A total of 21 patients (11
women) were recruited and 20 of them underwent RYGB sur-
gery with 1 participant undergoing sleeve gastrectomy. Preop-
eratively, the mean weight of patients was 152.5 26.4 kg and
mean BMIwas 52.13 7.5 kg/m2. Themean age of participants
was44.36.5 years.Weightwasmeasured to thenearest 0.1kg,
using a Seca 665 (Seca Ltd). Height was measured to the nearest
0.1 cm using a Seca 242 stadiometer (Seca Ltd). BMI was cal-
culated using kilograms per meter squared. Blood pressure was
recorded as the mean of 3 recordings using a mercury sphygmo-
manometer with the participant sitting.
For gene expression assays, archived tissue samples were also
used from patients who had undergone bariatric surgery in St
Columcille’s Hospital previously (43, 44). These adipose tissue
samples were snap frozen in liquid nitrogen and stored at80°
C. Omental and sc tissue samples from 24 nonobese patients
undergoing elective abdominal surgery in the Queen Elizabeth
hospital in Birmingham were used as a control group for gene
expression (15women,mean age 63.8 11.5y andmedian BMI
was 24 kg/m2, interquartile range [IQR] 23.3–24.3 kg/m2).
Results
Patient metabolic changes following bariatric
surgery
There were improvements in several measures of met-
abolic health following bariatric surgery. The mean pre-
operative BMIwas 52.1 7.5 kg/m2 and this decreased to
34.9 5.5 kg/m2 (P  .0001) following bariatric surgery.
The mean preoperative weight was 152.5 26.4 kg, and
104.8  20.7 kg (P  .0001) at repeat testing following
surgery. The mean systolic blood pressure (BP) preoper-
atively was 139  14.75 mmHg and this decreased to
123.212.32mmHg (P .0002).Diastolic BP improved
significantly from 86.7  10.5 mmHg to 74.1  8.8
mmHgpostoperatively (P .014). The cholesterol profile
did not improve significantly after RYGB surgery. Total
cholesterol was 4.5  0.9 mmol/L preoperatively and
4.2  0.8 postoperatively (P  .4). LDL was 2.8  0.6
mmol/L preoperatively and to 2.4 0.6 mmol/L postop-
eratively (P .08). HDL remained unchanged before and
after RYGB surgery at 1.3  0.3 mmol/L. Triglycerides
were 1.1 0.4mmol/L preoperatively and 0.9 0.3 post-
operatively (P .3). Despite a lack of significant changes
in lipid profiles, only 3 patients were on statin therapy
after weight loss, whereas 9 patients were on statins prior
to surgery. Fasting plasma glucose was 6.3 mmol/L (IQR
5.7–7.3) preoperatively and was significantly lower fol-
lowing RYGB surgery at 4.9mmol/L (IQR 4.8–5.9), (P
.001).HbA1Cdecreased significantly from43 (IQR37.5–
52.5) to 37.5 mmol/mol (IQR 33–39), (P  .005).
Hepatic 11ß-HSD1 activity (cortisol generation
profile)
All participants suppressed their morning fasting cor-
tisol levels to 50 nmol/L following 2mgdexamethasone
ingestion the previous night, before and after bariatric
surgery. The mean fasting cortisol level after dexametha-
sone suppression was 13.7 11.1 nmol/L preoperatively
and 12.1 5.2 nmol/L afterweight loss. The peak cortisol
generated following 25 mg oral cortisone acetate was
160.4  105.6 nmol/L preoperatively and this rose to
248.3 75.3 nmol/L after weight loss. Comparing results
before and after weight loss, there was an increase in cor-
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Figure 2. Analysis of serum cortisol, cortisone, and cortisol/cortisone (F/E) ratio before and after weight loss following bariatric surgery.
Analysis of pooled microdialysis subcutaneous adipose tissue samples of 16 patients undergoing bariatric surgery before and after weight
loss (G  H). All samples taken after ingestion of oral 25 mg cortisone acetate. A, Serum cortisol generation time curve. B, AUC analysis of
serum cortisol with significant increase in AUC serum cortisol after weight loss. C, Serum cortisone time curve. D, AUC analysis of serum
cortisone shows a significant increase after bariatric surgery. E, Time curve of ratio of F/E. F, AUC of F/E analysis with a significant increase in
postop F/E ratio. G, Microdialysis sc tissue cortisol generation of cortisol after ingestion of 25 mg oral cortisone acetate. H, AUC shows a
threefold reduction in F/E ratio after weight loss following bariatric surgery. Data expressed as means  SEM. Pre-op, black filled-in circe;
Post-op, grey filled-in inverted triangle.
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tisol generated at each time point postoperatively (Figure
2A), and area under the curve (AUC) analysis showed a
statistically significant increase in total cortisol generated
(26 768  16 880 vs 47 579  16 086 nmol/L/min, P 
.0001), (Figure 2B). Fasting serum cortisone preopera-
tivelywas 5.04.5nmol/L compared to3.41.2nmol/L
postoperatively, (P .9, Figure 2C). Peak serumcortisone
was 30.5  12.1 nmol/L preoperatively and 40.1  18
nmol/L postoperatively (P .1, Figure 2C). At each time
point, during the 240-minute cortisol generation profile,
cortisone was higher in the postoperative setting (Figure
2C). AUC analysis revealed a statistically significant dif-
ference after bariatric surgery, 5739  2048 vs 7523 
2815 nmol/min (P  .01, Figure 2D).
Finally, we looked at the ratio of cortisol to cortisone
(F/E). Serum F/E AUC was significantly raised after bari-
atric surgery showing as increase in hepatic 11-HSD1
activity (Figure 2E). The mean AUC for the F/E ratio was
943.8 (729.4–1097) preoperatively vs 1486 U (1067–
1547) postoperatively (P  .02, Figure 2F).
Subcutaneous adipose tissue microdialysis
Analysis of microdialysis samples from sc adipose tis-
sue demonstrated a reduction in 11-HSD1 activity after
weight loss in sc adipose tissue as seen by a threefold re-
duction in the F/E ratio between pooled pre and post-
RYGB surgery samples (Figure 2, G and H).
Urinary glucocorticoids and metabolites
Total cortisol excretion was not statistically different
before and after bariatric surgery. Similarly, there was no
difference in total cortisone excretion following weight
loss (Table 1). (THF5THF)/THE, a marker of global
11-HSD1 activity was not significantly different follow-
ing weight loss. The ratio of cortisol to cortisone (F/E),
which represents total body 11-HSD2 activity, remained
unchanged following weight loss (0.73  0.14 vs 0.75 
0.18, P  .7). There were significant reductions in the
corticosteroid metabolites THF, 5THF, and THE after
weight loss (Table 1). There was a statistically significant
reduction in total F metabolites (Figure 3A) following
weight loss (15 224 6595 vs 8814 4824g/24 h, P
.009) and a significant reduction in urinary dehydroepi-
androsterone (dehydroepiandrosterone [DHEA], Figure
3B) afterweight loss (622.5696vs 106.8131.6g/24
h, P  .02).
Tissue mRNA expression
Expression of 11-HSD1 was significantly higher in
adipose tissue depots in our obese cohort compared to
nonobese controls (Figure 4A). In omental adipose tissue,
11-HSD1 (Figure 4A) and glucocorticoid receptor (GR)
(Figure 4C)were significantly higher in severely obese pre-
operative patients compared to nonobese controls, 0.29
0.21 vs 0.17  0.12 AUs (P  .02) and 0.52  0.3 vs
0.32  0.19 AUs (P  .03), respectively. Subcutaneous
adipose tissue in preoperative severely obese patients had
significantly higher expression of 11-HSD1 (Figure 4B)
compared to nonobese controls (0.41  0.28 vs 0.23 
0.17 AUs, P  .03). Following surgery and weight loss,
there was a statistically significant drop in 11-HSD1 ex-
Table 1. Patient Clinical, Biochemical, and Anthropometric Characteristics.
Before Bariatric
Surgery
After Bariatric
Surgery
n  21 (male  10) n  18 (male  10) P Value
Weight (kg) 152.5  26.4 104.8  20.7 .0001
BMI (kg/m2) 52.13  7.5 34.9  5.5 .0001
HbA1C (mmol/mol) 43 (37.5–52.5) 37.5 (33–39) .005
Corticosteroid Metabolite (g/24 h) (n  11) (n  16)
Total Cortisol (F) 81  40.1 65.1  31.2 .7
Total Cortisone (E) 116.7  63.8 88.2  34.6 .3
F/E 0.73  0.14 0.74  0.16 .7
(THF5THF)/THE 0.86  0.15 0.94  0.36 .9
Total F metabolites 15 224  6595 8814  4824 .009
Androsterone 2970  1533 2706  1935 .7
Etiochoanolone 2070  1082 1387  1082 .14
17 OH Progesterone 129.3  76 131  109.4 .9
DHEA 622.5  696 106.8  131.6 .02
THF 2453  1140 1480  885.3 .02
5THF 2096  858.4 1212  866.9 .02
THE 5628  2986 3213  2157 .02
Abbreviation: 5THF, allo-tetrahydrocortisol. Data expresssed as means  SD for parametric data and medians and interquartile ranges for non-
Gaussian data. Urinary corticosteroid metabolites analyzed on gas chromatography mass spectrometry, data expressed as means  SD. After
weight loss there is a significant reduction in total F metabolites (CortisolTHF5THFCortolCortolCortisoneCortolone
CortoloneTHE) and DHEA. Total body 11-HSD1 activity {(THF5THF)/THE} and total body 11-HSD2 activity (UFF/UFE), remains unchanged
following bariatric surgery.
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pression in sc adipose tissue compared to preoperative
levels (0.41  0.28 vs 0.17  0.1 AUs, P  .03). Expres-
sion of GR in sc adipose tissue (Figure 4D) was lower in
nonobese controls compared to severely obese patients,
but this was not statistically significant (0.2  0.14 vs
0.34  0.23 AUs, P  .08).
When results of archived samples from previous bari-
atric surgery patients are added, analysis shows a positive
correlation between 11-HSD1 expression in omental ad-
ipose tissue and BMI (spearman r   0.52, P  .0001,
Figure 5A) but not sc adipose tissue (spearman r0.28,
P  .17, Figure 5B). Hepatic 11-HSD1 expression neg-
atively correlated with BMI (Pearson r0.37, P .04,
Figure 5C).
Discussion
In this study we characterize the dis-
cordance in tissue specific cortisol
metabolism between adipose tissue
depots and liver in a severely obese
cohort before and after significant
weight loss. Serum cortisol genera-
tion, reflecting hepatic 11-HSD1
activity (due to first passmetabolism
of oral cortisone acetate), was signif-
icantly increased after weight loss.
Therewasan increase in cortisol gen-
eration at each time point postoper-
atively (Figure 2A) andAUC showed
a statistically significant increase in
total cortisol generated (Figure 2, A
and B). Serum F/E AUCwas also sig-
nificantly raised after bariatric sur-
gery (Figure 2E). There was a signif-
icant increase in AUC of cortisone
postoperatively (Figure 2D). This
may reflect altered and increased ab-
sorption of orally ingested cortisone
acetate following gastric surgery or
alterations in metabolism.
Previous studies assessing a very
low calorie diet (VLCD) to achieve
weight loss, failed to show a change
in hepatic 11-HSD1 activity (19),
but this is the first study to our
knowledge to analyze hepatic 11-
HSD1 activity in a severely obese co-
hort before and after bariatric sur-
gery. Reduction in hepatic 11-
HSD1 activity may be a protective
mechanism in obesity to protect
against excessive hepatic cortisol ex-
posure (45) from omental adipose
tissue cortisol generation which is delivered via the portal
vein. In contrast to the increased hepatic 11-HSD1 ac-
tivity with weight loss, reduced 11-HSD1 activity and
expression was seen in sc tissue following weight loss.
Subcutaneous adipose tissue microdialysis revealed a
threefold reduction in cortisol/cortisone ratio in postop-
erative patients, suggesting a reduction in sc adipose tissue
activity of 11-HSD1 following weight loss. In a study
examiningweight loss using aVLCD,Tomlinson et al (29)
did not demonstrate a significant change in AUC cortisol
production in sc adipose tissue although this was a lower
BMI group and relied on VLCD to achieve significant
weight loss.
Figure 3. Urinary corticosteroid metabolites from BARICORT patients and control data. A, Total
urinary corticosteroid metabolites in severely obese patients undergoing bariatric surgery shows a
significant reduction in total F metabolites after weight loss. Control data from nonobese and
obese participants demonstrate a stepwise increase in total F metabolites with increasing BMI
category. Panel B shows urinary DHEA significantly reduced after bariatric surgery. Data
expressed as means  SEM. Pre-op BMI range 37–64 kg/m2. Post-op BMI range 27–40 kg/m2.
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Few studies have been published assessing 11-HSD1
expression and activity in humans specifically around
bariatric surgery. The bulk of data to date reflects women
undergoing bariatric surgery in Sweden (21, 27). In rodent
models, increased 11-HSD1 expression and activity is
associated with obesity and metabolic dysfunction. 11-
HSD1 knockout mice are resistant to the metabolic side
effects of ahigh-fat diet compared towild type (46).Trans-
genic mice, with overexpression of
11-HSD1 specifically in adipose
tissue, gainmoreweight and develop
metabolic complications compared
to the wild type (47).
In our cohort, omental 11-
HSD1 expression was significantly
higher in severely obese persons
compared to nonobese controls (Fig-
ure 4A). Leyvraz et al (48) showed
similar higher omental expression of
11-HSD1 compared to controls
howeverMichalaki et al (49) did not
show an increase in 11-HSD1
omental expression. Torrecilla et al
(26) similarly did not find associa-
tions between 11-HSD1 omental
expression in patients with severe
obesity and metabolic syndrome.
Gene expression of 11-HSD1 in
subcutaneous adipose tissue in our
cohort showed elevated levels com-
pared to nonobese controls. 11-
HSD1 expression in subcutaneous
adipose tissue was significantly re-
duced after weight loss, similar to
previous studies (21, 48). Leyvraz et
al (48) showed severely obese pa-
tients preoperatively have elevated
subcutaneous adipose tissue 11-
HSD1 gene expression levels com-
pared to nonobese controls and after RYGB surgery this
gradually reduced similar to nonobese controls.However,
Tomlinson et al (19) found an increase in expression of
11-HSD1 in sc adipose tissue after low calorie induced
weight loss. Unlike previous studies we also show a
matched reduction in 11-HSD1 activity in sc depot using
in vivo microdialysis which has not been shown before in
this cohort type. In our results, subcutaneous 11-HSD1
Figure 4. Expression of 11-HSD1 and GR from omental and sc adipose tissue in patients
undergoing bariatric surgery compared to nonobese controls. Data expressed in arbitrary units
(AUs) and as means  SEM. Unpaired t-test used to compare parametric data sets and Mann
Whitney U test used to compare nonparametric data. Adipose tissue from nonobese patients
undergoing elective abdominal surgery was used as controls. Severely obese patients undergoing
bariatric surgery had a significantly higher expression of 11-HSD1 and GR in omental adipose
tissue (A and C). Severely obese patients had a significantly higher expression of 11-HSD1 in sc
adipose tissue (B). After weight loss, Baricort sc tissue had similar expression of 11-HSD1
compared to nonobese controls (B) but not in GR expression.
Figure 5. Correlations between BMI and 11-HSD1 gene expression in all patients including archived tissue samples. A, Significant statistical
positive correlation between BMI and omental 11-HSD1 expression. C, Significant negative correlation between hepatic 11-HSD1 expression
and BMI.
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expression is slightly higher than in omental tissue, which
broadly speaking is in keeping with studies to date. Some
studies have shown similar expression of 11-HSD1 be-
tween visceral and subcutaneous compartments (9, 50,
51). However, they demonstrated different levels of ex-
pression of H6PDH and GR between depots (9), whereas
we show a difference only in GR in the omental depot
(Figure 4C). In subcutaneous adipose tissueGR is reduced
inpreoperative samples butnot significantly reduced com-
pared to nonobese controls (Figure 4D). When analyzing
our samples with archived tissue samples, we found a pos-
itive correlation with BMI and 11-HSD1 in omental ad-
ipose tissue but not subcutaneous adipose tissue. Hepatic
11-HSD1 expression also correlated inverselywith BMI.
Baudrand et al (24) found an inverse correlationwith BMI
and hepatic 11-HSD1 expression in patients undergoing
bariatric surgery. However, Tomlinson et al in 2001 did
not find a correlation with adipose tissue 11-HSD1 ex-
pression and BMI (18) (Figure 5).
By assessing urinary corticosteroid metabolites, we
have shown that global 11-HSD1 and 11-HSD2 activ-
ity, remains unchanged before and after significantweight
loss. However, in different metabolic tissues, we show
different changes (increases and decreases) in 11-HSD1
activity and expression, in response to significant weight
loss after bariatric surgery. Global 11-HSD1 activity, as
reflected by [(THF5THF)/THE], in our study was not
significantly different before and after surgery in keeping
with earlier short studies using low calorie diets (22, 29).
In a study assessing women undergoing RYGB surgery,
Rask et al (27), demonstrated a significant total reduction
in urinary glucocorticoid metabolites after weight loss, as
reflected by the ratio (THF5THF)/THE. Global 11-
HSD1 activity, includes 11-HSD1 activity in adipose,
hepatic, and skeletalmuscle aswell as several other tissues.
Global 11-HSD1 activity remains similar before and af-
ter bariatric surgery. Given our findings of increased he-
patic 11-HSD1 activity and reduced subcutaneous 11-
HSD1 activity after weight loss, the unchanged global
11-HSD1 activity may be explained by a combination of
altering 11-HSD1 activity in liver, adipose tissue, and
possibly muscle to compensate each other. Cortisol and
cortisone secretion were not statistically different before
and after bariatric surgery. The ratio of cortisol/cortisone
(UFF/UFE), which represents total body 11-HSD2 activ-
ity, also remained unchanged followingweight loss, again
in contrast to Rask et al (27).
Interestingly, a significant reduction in total cortisol
metabolites is seen, including DHEA. This suggests a re-
duction in ACTH drive and reduction in HPA axis activ-
ity, which perhaps compensates for the increased hepatic
11-HSD1 activity. There were nonsignificant reductions
in androsterone, etiocholanolone, and 17-hydroxypro-
gesterone. DHEA is under the influence of ACTH and the
observed reduction supports our theory of a reduction in
pituitary ACTH secretion following weight loss in this
bariatric cohort. This altered HPA axis following weight
loss has been suggested by previous authors (22).
Our data suggest alterations in glucocorticoid metab-
olism in severe obesity, with tissue specific changes fol-
lowing weight loss due to bariatric surgery. 11-HSD1
expression and activity is increased in adipose tissue in
severelyobesepatientswitha reduction in liver11-HSD1
activity, potentially as a protective mechanism (in order
not to exacerbate the significant hepatic cortisol delivery
from omental adipose tissue). Importantly, weight loss
leads to dynamic changes in omental, hepatic, and total
body glucocorticoid metabolism.
Specific inhibitors of 11-HSD1have been investigated
in small clinical trials, primarily in the area of type 2 di-
abetes and themetabolic syndrome (33, 34). All published
datahavedemonstratedmodest but significantweight loss
in patients who received 11-HSD1 inhibitors. However,
given our findings in this study (and those of others), high-
lighting the tissue specific changes in glucocorticoid me-
tabolism after weight loss, an adipose tissue specific in-
hibitor of 11-HSD1 may potentially be more efficacious
than a global specific 11-HSD1 inhibitor.
In summary, we have shown that in severely obese in-
dividuals undergoing bariatric surgery, hepatic 11-
HSD1 activity increases after weight loss and subcutane-
ous 11-HSD1 activity is reduced after weight loss.
Omental and liver tissue 11-HSD1 expression correlates
with BMI. Compared to nonobese controls, 11-HSD1
expressionwas higher in adipose tissue, both omental and
subcutaneous and thesewere reduced post-RYGB.Global
F metabolites in urine were reduced after weight loss in-
dicating a reduction in HPA axis activity. This study fur-
ther elucidates the role 11-HSD1 has in different meta-
bolic tissues in obesity.
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